Discovery on Target
Discovery on Target Mobile Header

CONFERENCE SERIES: Drug Discovery & Development

Recorded at: The Bioprocessing Summit

Digital Course: Pharmacology and Drug Discovery in the Allosteric World

 

 

Order DVD2012 DOT DVD Cover About this Product: 

The advancing technology of high-throughput screening is changing the type of molecules found. With protein function more physiologically relevant, the quality of the molecules that pharmacologists and medicinal chemists must deal with is changing. This course will familiarize researchers with the tools needed to exploit this potentially fruitful area of new drug discovery through discussion of allosteric molecules, detection of allosterism, and quantifying allosterism for chemical lead optimization. The course is designed to answer these questions:

What is protein allostery?
What makes allosteric molecules unique and how can this contribute to unique therapeutic properties?
How can we detect allosterism?
How to quantify allosterism for chemical lead optimization?

Preview: 

 

About this Product:
2 Presentations
141 Slides
Over 113 Minutes
Individual: $345
Site License: $1380

Conference At A Glance: 

Terrence KenakinTerry P. Kenakin, Ph.D., Professor, Department of Pharmacology, University of North Carolina School of Medicine 
Terry Kenakin is Research Professor in the Department of Pharmacology, University of North Carolina School of Medicine, Chapel Hill, North Carolina. Terry obtained his B.S. in chemistry and Ph.D. in Pharmacology at the University of Alberta, Canada. After 3 years at University College, London, UK, he joined Burroughs-Wellcome as a Senior Research Pharmacologist. Terry then went on to join Glaxo, which became Glaxo-Wellcome and subsequently GlaxoSmithKline, where his work involved the use of quantitative receptor pharmacology and theory to advance new drug discovery programs. He applies quantitative pharmacologic concepts to drug dose-response data to provide medicinal chemists with scales to optimize drug activity. He has written 9 books on Pharmacology and is co-Editor-in-Chief of the Journal of Receptors and Signal Transduction and also Current Opinion in Pharmacology. His current interests center on the therapeutic exploitation of the 7TM receptor functional selectivity and allosteric control of the 7TM receptor signaling.

Annette GilchristAnnette Gilchrist, Ph.D., Assistant Professor, Pharmaceutical Sciences, Midwestern University
Annette Gilchrist received her M.S. in Biochemistry from the University of Connecticut and Ph.D. in Immunology from the University of Connecticut Health Center. Following a postdoctoral fellowship with Dr. Heidi Hamm, Dr. Gilchrist went on to cofound Caden Biosciences and Cue BIOtech, companies committed to GPCR drug discovery efforts. Currently, Dr. Gilchrist is an Assistant Professor in the Department of Pharmaceutical Sciences at Midwestern University’s Chicago of Pharmacy, and an Adjunct Professor at Northwestern University in the Department of Molecular Pharmacology and Biological Chemistry. Her work is focused on functional selectivity and allosteric regulation of GPCRs. Dr. Gilchrist has twenty-five peer-reviewed publications and four issued patents including a just publishedmanuscript that was cited as a "must read" by the Faculty of 1000. In addition, she recently served as editor for a book by Wiley entitled GPCR Molecular Pharmacology and Drug Targeting: Shifting Paradigms and New Directions 

About Discovery On Target: 

Discovery on Target is known as the leading event showcasing novel "hot" targets for the pharmaceutical industry will be held November 2-4 in Boston, Massachusetts at the historic Park Plaza Hotel & Towers.

This is a must attend event to keep up with current and upcoming developments in target discovery and to collaborate and connect with experienced scientists and high level decision makers.

Networking opportunities will be available through interactive sessions including roundtable breakouts, workshops and panel discussions.

Create your own agenda by moving between the conference programs and choose the sessions that best fit your research and networking needs.

Japan-Flag Korea-Flag China-Simplified-Flag China-Traditional-Flag  

Final Agenda Now Available

Final Agenda Now Available


 PREMIER SPONSOR

Cellecta

Arrow DownCONFERENCE-AT-A-GLANCE

Arrow DownDOWNLOAD 2016 BROCHURE

Arrow OverSHORT COURSES

Arrow OverVIEW ALL SPONSORS

Arrow OverVIEW MEDIA PARTNERS


SPONSORSHIPS & EXHIBITS

The exhibit hall was sold out in 2015, so please contact us early to reserve your place. To customize your sponsorship or exhibit package for 2016, contact:

Jon Stroup
Sr. Business Development Manager
781-972-5483
jstroup@healthtech.com

 

Sponsorship-vid

DOT-Vid-recap 

IPR-Special-Report-Packages  

SEPTEMBER 19 SYMPOSIA:

Next-Generation Histone Deacetylase Inhibitors

Strategies for Tackling Rare Genetic Diseases

Understanding CRISPR: Mechanisms and Applications

Autoimmunity – Small Molecule Approaches

NK Cell-Based Cancer Immunotherapy

CONFERENCES

SEPTEMBER 20-21

Targeting Histone Methyltransferases and Demethylases

Targeting the Ubiquitin Proteasome System

Targeting the Microbiome
– Part 1

GPCR-Based Drug Discovery - Part 1

Advances in Gene Editing and Gene Silencing – Part 1

Gene Therapy Breakthroughs

Antibodies Against Membrane Protein Targets – Part 1

Targeting Cardio-Metabolic Diseases

Targeting Ocular Disorders

SEPTEMBER 21-22

Targeting Epigenetic Readers and Chromatin Remodelers

Kinase Inhibitor Discovery

Targeting the Microbiome
– Part 2

GPCR-Based Drug Discovery - Part 2

Advances in Gene Editing and Gene Silencing – Part 2

Translating Cancer Genomics

Antibodies Against Membrane Protein Targets – Part 2

Metabolomics in Drug Discovery

TRAINING SEMINAR: Data Visualization

SHORT COURSES*

Monday, September 19
8:00 - 11:00 am

(SC1) Immunology Basics for Chemists

(SC2) Designing Peptide Therapeutics for Specific PPIs

(SC3) Phenotypic Screening and Chemical Probe Development

(SC4) Medical Dermatology Therapeutic R&D and Technical Innovation - Part 1

Monday, September 19
2:00 - 3:00 pm

(SC5) GPCR Structure-Based Drug Discovery

(SC6) RNA as a Small Molecule Drug Target

(SC7) Using IP Landscape Studies to Improve Your Confidence

(SC8) Medical Dermatology Therapeutic R&D and Technical Innovation - Part 2

Monday, September 19
3:30 - 6:30 pm

(SC9) Targeting of GPCRs with Monoclonal Antibodies

(SC10) Introduction to Targeted Covalent Inhibitors

(SC11) Contact Lens Drug Delivery Systems

(SC12) Introduction to Gene Editing

Monday, September 19
7:00 - 9:30 pm

(SC13) Convergence of Immunotherapy and Epigenetics for Cancer Treatment

Wednesday, September 21
7:00 - 9:30 pm

(SC14) Cancer Metabolism: Pathways, Targets and Clinical Updates

(SC15) Introduction to Allosteric Modulators and Biased Ligands of GPCRs

(SC16) Functional Screening Strategies Using CRISPR and RNAi

(SC17) Challenges and Opportunities in DNA Methyl Transferase (DNMT) Inhibitors as Therapeutics